NIH Scientists Develop Promising Non-Addictive Treatment for Cancer Pain

Scientists at the National Institutes of Health (NIH) have announced encouraging results from a first-in-human clinical trial using resiniferatoxin (RTX), a plant-derived molecule, to manage intractable cancer pain. This new therapy, administered through a single lumbar injection, significantly reduced pain intensity and decreased opioid use among patients with advanced-stage cancer, offering hope for individuals who have found little relief with conventional treatments.

In the clinical trial, patients experienced a 38% reduction in their worst pain levels and a 57% decline in their reliance on opioid medications. Participants, who had been resistant to standard pain interventions, reported improvements in their overall quality of life, including enhanced ability to engage with family and friends without the heavy sedation typically caused by opioids. RTX’s effectiveness lies in its ability to deactivate specific nerve fibers responsible for transmitting pain and heat signals to the brain, while preserving other sensory functions like touch and proprioception.

RTX is a potent activator of the TRPV1 ion channel, a target for pain signal transmission. Its unique mechanism floods the targeted nerve fibers with calcium, effectively blocking their ability to send pain messages without causing the generalized numbness associated with local anesthetics. Unlike other methods that non-selectively damage nerves, RTX offers highly specific pain relief without impairing motor function or other sensations.

Derived from the Euphorbia resinifera plant native to North Africa, RTX has a long history of medicinal use, but only now has it been translated into a targeted pain therapy through decades of NIH research. The promising results of this early clinical trial have prompted plans for expanded studies, with the goal of obtaining U.S. Food and Drug Administration approval and making RTX available as a new option for pain management. Researchers believe the therapy could eventually be applied to a variety of other chronic and post-surgical pain conditions.

Article by multiple RFHC contributors, based upon information from the National Institutes of Health (NIH) press release.

---